TapImmune to Participate at Two Upcoming Industry Conferences
JACKSONVILLE, Fla., Aug. 29, 2018 /PRNewswire/ --TapImmune Inc. (NASDAQ : TPIV ), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming industry conferences. Mr. Hoang will present and participate in a panel discussion at the Hanson Wade CAR-TCR Summit, to be held September 4-7, 2018, in Boston, Massachusetts, and present at BioCentury's 25th Annual NewsMakers in the Biotech Industry to be held September 7, 2018, in New York City.
CAR-TCR Summit Details:
Date: Wednesday, September 5, 2018
Location: Cityview Room; Seaport Hotel and World Trade Center, Boston, MA
Time: 2:25pm (ET): Company Presentation
5:15pm (ET): Panel - How to Make CAR/TCR Therapies Work Beyond the CD19/ALL Paradigm
BioCentury Newsmakers Presentation Details:
Date: Friday, September 7, 2018
Location: Millennium Broadway Hotel & Conference Center, New York City, NY
Time: 2:30pm (ET): Presentation - Room 302/303
3:00pm (ET): Breakout Session - Room 301
Webcast: Available at http://www.tapimmune.com/events
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The Company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T cell vaccine candidates that elicit a broad-based T cell response and can be used without respect to HLA type. The Company's technologies may be used as stand-alone medications or in combination with other treatment modalities. TapImmune has announced a proposed merger with Marker Therapeutics, Inc., a privately-held clinical stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform, which will add a significant portfolio of clinical-stage cell therapies to create a leading immuno-oncology pipeline.
For additional information, please visit: https://tapimmune.com/
To receive future press releases via email, please visit:
Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.
For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.